Business Context and Reporting Period
This Form 6-K filing by Chemomab Therapeutics Ltd. covers the month of April 2026. The report serves as a notification regarding the adjournment of the Company's Annual General Meeting of Shareholders originally scheduled for April 28, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the adjournment of the Annual General Meeting due to a lack of quorum. The meeting has been rescheduled to Tuesday, May 5, 2026, at 4:30 p.m. (Israel time) at the same location in Ramat Gan, Israel.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It references a prior Form 6-K filed on March 20, 2026, which included the proxy statement and proposed resolutions for the meeting. No new risks or contingencies are disclosed in this specific text.
Key Facts for Investors
- The Annual General Meeting was adjourned on April 28, 2026, due to insufficient shareholder attendance (lack of quorum).
- The rescheduled meeting date is May 5, 2026, at the same time and venue as the original meeting.
- Details regarding the agenda and proposed resolutions are contained in the proxy statement filed on March 20, 2026.
- This filing incorporates by reference into the Company's active Registration Statements on Form F-3 and Form S-8.